Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brixadi Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Adversity, Brain and Opioid Use Study

NCT06355778
View directory record Official record
Conditions
Opioid Use Disorder, Healthy
Interventions
Magnetic Resonance Imaging (MRI), Computer Tasks
Other · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

NCT00015340
View directory record Official record
Conditions
Opioid Dependence, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Enrollment
582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Hines, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 6:28 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 1 Interventional

Improved Strategies for Outpatient Opioid Detoxification

NCT01377610
View directory record Official record
Conditions
Opioid Dependence
Interventions
oral naltrexone, Buprenorphine, Vivitrol
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 22, 2026, 6:28 PM EDT
Not listed No phase listed Observational

Improving Treatment and Recovery Services for Individuals With Opioid Problems

NCT05129813
View directory record Official record
Conditions
Counseling
Interventions
Recovery Guide Counseling
Behavioral
Lead sponsor
Howard University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 22, 2026, 6:28 PM EDT
Recruiting Early Phase 1 Interventional

Pilot of Mailing Buprenorphine

NCT07421102
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
strategy of mailing buprenorphine
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

NCT00313014
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine, Oxycodone Immediate-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
85
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 3 Interventional

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171
View directory record Official record
Conditions
Heroin Dependence, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 22, 2026, 6:28 PM EDT
Terminated Phase 4 Interventional Results available

Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization

NCT05118204
View directory record Official record
Conditions
Substance Use Disorders, Opioid-use Disorder, Chronic Pain
Interventions
BUP microdose induction, TAU, Linkage to outpatient BUP treatment
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Not applicable Interventional

MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE)

NCT02942199
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MySafeRx
Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 39 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 22, 2026, 6:28 PM EDT
Recruiting Not applicable Interventional

Integrating MOUD in Nonmedical Community Settings (Better Together)

NCT06416020
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
HC-MOUD Only, BT-MOUD with Buprenorphine
Behavioral
Lead sponsor
Howard University
Other
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Recruiting Not applicable Interventional

PRoducing Outcome Measures for OTP Quality Improvement

NCT07214389
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Quality Measures (Audit and Feedback), Quality Improvement (QI) Toolkit, External QI Facilitation
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

NCT02665208
View directory record Official record
Conditions
Smoking Cessation
Interventions
Treatment As Usual (TAU), Nicotine Replacement Therapies, Text Message Intervention (TMI)
Other · Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 22, 2026, 6:28 PM EDT
Recruiting Not applicable Interventional

Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine

NCT07278518
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Patient Decision Aid for Opioid Use Disorder
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 22, 2026, 6:28 PM EDT
Not listed Phase 4 Interventional

Buprenorphine and Integrated HIV Care Evaluation

NCT00124358
View directory record Official record
Conditions
Opioid-Related Disorders, HIV Infections, AIDS
Interventions
Buprenorphine, Integrated HIV care and office-based opioid dependence treatment
Drug · Behavioral
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2007 · Synced Oct 22, 2026, 6:28 PM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

NCT06521476
View directory record Official record
Conditions
Central Sleep Apnea Comorbid With Opioid Use
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Sanjay R Patel
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

NCT00032968
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Berkeley, California • Oxnard, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

SSRI and Buprenorphine

NCT00475878
View directory record Official record
Conditions
Opiate Dependence, Depression
Interventions
escitalopram, placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

NCT03254459
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride, Zofran
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Pasadena, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 22, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

NCT01324570
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine transdermal system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
7 Years to 16 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 22, 2026, 6:28 PM EDT